Control Bionics (ASX:CBL) raised around AU$2 million via a private placement to two existing shareholders, Nightingale Partners and Phoenix Development Fund, at an issue price of AU$0.045 per share, according to a Tuesday Australian bourse filing.
A total of 4.8 million shares were issued under the firm's share issue capacity.
It will use the proceeds to focus on revenue growth in its core operations and the expansion into new high-potential markets, including the NeuroNode Only and NeuroStrip platforms.
The firm's shares rose 4% on market close Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。